- Home
- MYN vs TSHA Comparison
MYN vs TSHA Comparison
Compare MYN & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYN
- TSHA
- Stock Information
- Founded
- MYN 1992
- TSHA 2019
- Country
- MYN United States
- TSHA United States
- Employees
- MYN N/A
- TSHA N/A
- Industry
- MYN Finance Companies
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- MYN Finance
- TSHA Health Care
- Exchange
- MYN Nasdaq
- TSHA Nasdaq
- Market Cap
- MYN 411.5M
- TSHA 334.1M
- IPO Year
- MYN N/A
- TSHA 2020
- Fundamental
- Price
- MYN $10.19
- TSHA $1.61
- Analyst Decision
- MYN
- TSHA Strong Buy
- Analyst Count
- MYN 0
- TSHA 8
- Target Price
- MYN N/A
- TSHA $6.63
- AVG Volume (30 Days)
- MYN 86.0K
- TSHA 2.1M
- Earning Date
- MYN 01-01-0001
- TSHA 02-26-2025
- Dividend Yield
- MYN 4.12%
- TSHA N/A
- EPS Growth
- MYN N/A
- TSHA N/A
- EPS
- MYN N/A
- TSHA N/A
- Revenue
- MYN N/A
- TSHA $9,915,000.00
- Revenue This Year
- MYN N/A
- TSHA N/A
- Revenue Next Year
- MYN N/A
- TSHA N/A
- P/E Ratio
- MYN N/A
- TSHA N/A
- Revenue Growth
- MYN N/A
- TSHA N/A
- 52 Week Low
- MYN $8.47
- TSHA $1.19
- 52 Week High
- MYN $10.62
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- MYN 50.49
- TSHA 46.14
- Support Level
- MYN $10.12
- TSHA $1.46
- Resistance Level
- MYN $10.29
- TSHA $1.76
- Average True Range (ATR)
- MYN 0.07
- TSHA 0.15
- MACD
- MYN 0.00
- TSHA 0.01
- Stochastic Oscillator
- MYN 56.92
- TSHA 39.33
About MYN Blackrock MuniYield New York Quality Fund Inc.Common Stock
Blackrock Muniyield NY Quality FD, Inc is a closed-end management investment company. Its objective is to provide shareholders with a high level of current income exempt from federal income taxes. The Fund invests primarily in long-term municipal obligations that are investment grade quality or are considered by the Fund's investment adviser to be of comparable quality, at the time of investment.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.